Overview: Candida Albicans PCR TestIntroduction: The Candida Albicans PCR Test detects Candida albicans DNA, indicating fungal infections like thrush or skin rashes. Following 2023 IDSA guidelines, it uses PCR for high specificity, aiding in infectious disease screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in mycology for patients with suspected fungal infections.
Other Names: Candida PCR Assay, Fungal Infection Test.
FDA Status: Laboratory-developed test (LDT), meeting mycology standards for diagnostic accuracy.
Historical Milestone: Candida testing began in the 1970s with culture methods. PCR-based assays emerged in the 1990s, and by the 2000s, real-time PCR improved detection accuracy.
Purpose: Diagnoses Candida albicans infections, guides treatment, and monitors fungal presence in patients with thrush or skin rashes.
Test Parameters: 1. Candida Albicans DNA
Pretest Condition: No fasting required. Collect swab, sputum, body fluid, whole blood, urine, or saliva at any time. Report symptoms like thrush or rashes, and list medications like antifungals.
Specimen: 1-2 swabs (sterile swab/transport medium), 5-10 mL sputum (sterile container), 5-10 mL body fluid (sterile container), 2-5 mL whole blood (EDTA), 5-20 mL urine (sterile container), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document thrush, skin rashes, or risk factors like immunosuppression. Include current medications, especially antifungals or immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antifungal therapy.
Procedural Considerations: Uses PCR to detect Candida albicans DNA. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Improper storage or delayed transport can degrade DNA. Antifungals may reduce sensitivity.
Clinical Significance: Positive results confirm Candida albicans infection, prompting antifungal therapy. Negative results may require culture or antigen testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation. A dermatologist referral is advised for skin involvement.
Additional Supporting Tests: Candida culture, mannan antigen test, or imaging to confirm infection or assess extent.
Test Limitations: False negatives may occur with low fungal loads. Results require clinical correlation.
References: IDSA Fungal Guidelines, 2023; Clinical Infectious Diseases, Pappas PG, 2022.
